Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.

Dr. Gordon Grado established a new program for the treatment of prostate cancer while Chairman of the Radiation Oncology Department of Mayo Clinic in Scottsdale. Tomotherapy is now used for several ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, today announced the appointment of ...

SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression ...

Targeted therapies are medicines to treat cancer. They work differently than standard chemotherapy. Instead of killing all fast-growing cells or keeping them from dividing, targeted therapies work ...